Treatment of HIV-1 infected patients with combinations of inhibitors of the viral protease (PR) and reverse transcriptase (RT) enzymes has been remarkably successful in suppressing viral replication and prolonging patient survival. However, extended administration of these antiretroviral (ARV) agents is commonly associated with the emergence of resistant virus that often compromises treatment. The clinical management of ARV treatment experienced patients has been greatly facilitated by the development of phenotypic and genotypic drug resistance assays. The increase in the prevalence and spread of drug-resistant virus, including strains displaying broad cross-resistance to PR and RT inhibitors has necessitated the development of new therapeutic approaches to combat this highly adaptive virus. Inhibitors of HIV entry represent a promising new class of antiretroviral agents. The development of phenotypic and genotypic assays to detect drug resistant strains will undoubtedly accelerate the development of entry inhibitors and improve their utility in the clinic. Phase I support was used to develop a phenotypic assay that measures susceptibility of HIV-1 to entry inhibitors and a genotypic assay that detects resistance mutations in the HIV-1 envelope gene. Phase II support is intended to optimize, scale and validate these two resistance tests for routine use in a clinical reference laboratory environment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI048990-03
Application #
6697010
Study Section
Special Emphasis Panel (ZRG1-AARR-3 (11))
Program Officer
Sharma, Opendra K
Project Start
2001-05-01
Project End
2006-07-31
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
3
Fiscal Year
2003
Total Cost
$801,731
Indirect Cost
Name
Monogram Biosciences, Inc.
Department
Type
DUNS #
945494490
City
South San Francisco
State
CA
Country
United States
Zip Code
94080
Bunnik, Evelien M; Swenson, Luke C; Edo-Matas, Diana et al. (2011) Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog 7:e1002106
Toma, Jonathan; Weinheimer, Steven P; Stawiski, Eric et al. (2011) Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol 85:3872-80
Huang, Wei; Frantzell, Arne; Toma, Jonathan et al. (2011) Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1. Virology 409:308-18
Toma, Jonathan; Whitcomb, Jeannette M; Petropoulos, Christos J et al. (2010) Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 24:2181-6
Huang, Wei; Eshleman, Susan H; Toma, Jonathan et al. (2009) Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. AIDS 23:1903-8
Huang, Wei; Toma, Jonathan; Stawiski, Eric et al. (2009) Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses 25:795-802
Huang, Wei; Toma, Jonathan; Fransen, Signe et al. (2008) Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 82:5584-93
Fransen, Signe; Bridger, Gary; Whitcomb, Jeannette M et al. (2008) Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrob Agents Chemother 52:2608-15
Mohri, Hiroshi; Markowitz, Martin (2008) In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr 48:511-21
Huang, Wei; Eshleman, Susan H; Toma, Jonathan et al. (2007) Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 81:7885-93

Showing the most recent 10 out of 14 publications